scholarly journals Blood Pressure Response Under Chronic Antihypertensive Drug Therapy

2009 ◽  
Vol 53 (5) ◽  
pp. 445-451 ◽  
Author(s):  
Athanase Protogerou ◽  
Jacques Blacher ◽  
George S. Stergiou ◽  
Apostolos Achimastos ◽  
Michel E. Safar
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Antihypertensive Drug ◽  
Blood Pressure Response ◽  
Pressure Response ◽  
Antihypertensive Drug Therapy

scholarly journals A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment

2021 ◽  
Author(s):  
Kazuomi Kario ◽  
Hideaki Kagitani ◽  
Shoko Hayashi ◽  
Satsuki Hanamura ◽  
Keisuke Ozawa ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Side Effects ◽  
Antihypertensive Drug ◽  
Patient Preference ◽  
Renal Denervation ◽  
Antihypertensive Drugs ◽  
Japanese Patients ◽  
Home Blood Pressure ◽  
Antihypertensive Drug Therapy

AbstractRenal denervation is a potential alternative to antihypertensive drug therapy. However, data on patient preference for this treatment option are limited and there are no data specifically from Asian patients. This study evaluated patient preference for renal denervation in patients with hypertension from Japan. Patients were a subset of those who participated in a March 2020 online electronic survey of patients with hypertension who had regularly visited medical institutions for treatment, were receiving antihypertensive drug therapy and had home blood pressure recordings available. The survey included a question about patient preference for treatment with renal denervation. A total of 2,392 patients were included (66% male, mean age 59.8 ± 11.6 years, mean duration of hypertension 11.4 ± 9.5 years). Preference for renal denervation was expressed by 755 patients (31.6%), and was higher in males than in females, in younger compared with older patients, in those with higher versus lower blood pressure, in patients who were less adherent versus more adherent to antihypertensive drug therapy, and in those who did rather than did not have antihypertensive drug-related side effects. Significant predictors of preference for renal denervation on logistic regression analysis were younger patient age, male sex, higher home or office systolic blood pressure, poor antihypertensive drug adherence, the presence of heart failure, and the presence of side effects during treatment with antihypertensive drugs. Overall, a relevant proportion of Japanese patients with hypertension expressed a preference for renal denervation. This should be taken into account when making shared decisions about antihypertensive drug therapy.

scholarly journals Interactions between five candidate genes and antihypertensive drug therapy on blood pressure

2005 ◽  
Vol 6 (1) ◽  
pp. 22-26 ◽  
Author(s):  
H Schelleman ◽  
B H Ch Stricker ◽  
W M M Verschuren ◽  
A de Boer ◽  
A A Kroon ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Candidate Genes ◽  
Antihypertensive Drug ◽  
Antihypertensive Drug Therapy

scholarly journals The chaos of hypertension guidelines for chronic kidney disease patients

2019 ◽  
Vol 12 (6) ◽  
pp. 771-777 ◽  
Author(s):  
Esmeralda Castillo-Rodriguez ◽  
Beatriz Fernandez-Fernandez ◽  
Raquel Alegre-Bellassai ◽  
Mehmet Kanbay ◽  
Alberto Ortiz
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Drug Therapy ◽  
Kidney Disease ◽  
Antihypertensive Drug ◽  
Secondary Hypertension ◽  
Antihypertensive Drug Therapy ◽  
Hypertensive Drug ◽  
Definition Of ◽  
Current Guidelines

Abstract Three major guidelines deal with blood pressure thresholds and targets for antihypertensive drug therapy in chronic kidney disease (CKD) patients: the 2012 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease; the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults; and the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. However, a careful reading of the three guidelines leaves the practicing physician confused about the definition of CKD, how hypertension and secondary hypertension should be diagnosed in CKD patients and what the blood pressure thresholds, targets and compelling indications of antihypertensive drug therapy should be for this population. Current guidelines refer to different CKD populations and propose different definitions of hypertension, different thresholds to initiate antihypertensive therapy in CKD patients and different BP targets compelling antihypertensive drug use. The different bodies producing guidelines should work together towards a unified definition of CKD, a unified concept of hypertension and unified BP thresholds and targets for hypertensive drug therapy for CKD patients. Otherwise they risk promoting confusion and therapeutic nihilism among physicians and patients.

Weight reduction versus antihypertensive drug therapy in obese men with high blood pressure

1992 ◽  
Vol 10 (9) ◽  
pp. 1053???1062 ◽  
Author(s):  
Bj??rn Fagerberg ◽  
Antje Berglund ◽  
Ove K. Andersson ◽  
G??ran Berglund
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
High Blood Pressure ◽  
Antihypertensive Drug ◽  
Weight Reduction ◽  
Antihypertensive Drug Therapy

scholarly journals Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.

1991 ◽  
Vol 2 (4) ◽  
pp. 927-936
Author(s):  
P A Abraham ◽  
M G Macres
Keyword(s):  
Blood Pressure ◽  
Drug Therapy ◽  
Diastolic Blood Pressure ◽  
Antihypertensive Drug ◽  
Antihypertensive Drugs ◽  
Pressure Control ◽  
Hemodialysis Patients ◽  
Uncontrolled Hypertension ◽  
Antihypertensive Drug Therapy ◽  
Dose Dependent

This study analyzed blood pressure in hemodialysis patients treated with epoetin beta in multicenter trials. Antihypertensive drugs were prescribed as usual. Placebo-controlled trials compared epoetin (100 to 150 U/kg; N = 151) with placebo (N = 78) for 82 days. Hemoglobin (108 +/- 18 versus 75 +/- 14 g/L) (mean +/- SD) and diastolic blood pressure (84 +/- 14 versus 78 +/- 15 mm Hg) were greater (P less than 0.05) after epoetin. Clinically important increases in blood pressure (increases in diastolic blood pressure greater than or equal to 10 mm Hg and/or drug therapy) were more frequent with epoetin (58 versus 37%; P = 0.005). A dose-response trial compared epoetin, 25 U/kg (N = 42), 100 U/kg (N = 40), and 200 U/kg (N = 39) for 138 days. Increases in hemoglobin were dose dependent, but clinically important increases in blood pressure were not. In analyses of all patients treated with epoetin (N = 272), no baseline or final level of hemoglobin, or rate of hemoglobin rise, was a threshold for a rise in blood pressure. Patients requiring antihypertensive drugs or having uncontrolled hypertension (diastolic blood pressure greater than 90 mm Hg) at baseline had decreases in blood pressure (P less than 0.05) with antihypertensive therapy. Thus, compared with placebo, 21% of patients had clinically important increases in blood pressure during amelioration of anemia. The baseline or final levels of hemoglobin, the extent or rate of hemoglobin rise, or uncontrolled hypertension or antihypertensive drug use at baseline were not confirmed as risks. Antihypertensive drug therapy was important for blood pressure control.

Sign in / Sign up

Export Citation Format

Share Document